Follow
Ryohei Katayama
Ryohei Katayama
Japanese Foundation for Cancer Research
Verified email at jfcr.or.jp
Title
Cited by
Cited by
Year
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
K Bergethon, AT Shaw, SH Ignatius Ou, R Katayama, CM Lovly, ...
Journal of clinical oncology 30 (8), 863-870, 2012
19912012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
R Katayama, AT Shaw, TM Khan, M Mino-Kenudson, BJ Solomon, ...
Science translational medicine 4 (120), 120ra17-120ra17, 2012
14872012
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
JF Gainor, L Dardaei, S Yoda, L Friboulet, I Leshchiner, R Katayama, ...
Cancer discovery 6 (10), 1118-1133, 2016
11572016
The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer
L Friboulet, N Li, R Katayama, CC Lee, JF Gainor, AS Crystal, ...
Cancer discovery 4 (6), 662-673, 2014
9302014
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ...
Science 346 (6216), 1480-1486, 2014
8082014
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
R Katayama, TM Khan, C Benes, E Lifshits, H Ebi, VM Rivera, ...
Proceedings of the National Academy of Sciences 108 (18), 7535-7540, 2011
6962011
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
JF Gainor, AM Varghese, SHI Ou, S Kabraji, MM Awad, R Katayama, ...
Clinical cancer research 19 (15), 4273-4281, 2013
6542013
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ...
Nature communications 6 (1), 6377, 2015
6062015
Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F
AT Shaw, L Friboulet, I Leshchiner, JF Gainor, S Bergqvist, A Brooun, ...
New England Journal of Medicine 374 (1), 54-61, 2016
5402016
PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models
HY Zou, L Friboulet, DP Kodack, LD Engstrom, Q Li, M West, RW Tang, ...
Cancer cell 28 (1), 70-81, 2015
4892015
Acquired resistance to crizotinib from a mutation in CD74–ROS1
MM Awad, R Katayama, M McTigue, W Liu, YL Deng, A Brooun, ...
New England Journal of Medicine 368 (25), 2395-2401, 2013
4692013
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
K Uchibori, N Inase, M Araki, M Kamada, S Sato, Y Okuno, N Fujita, ...
Nature communications 8 (1), 14768, 2017
3982017
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non–small-cell lung cancer
LV Sequist, S Gettinger, NN Senzer, RG Martins, PA Jänne, R Lilenbaum, ...
Journal of clinical oncology 28 (33), 4953-4960, 2010
3892010
Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels
D Morishita, R Katayama, K Sekimizu, T Tsuruo, N Fujita
Cancer research 68 (13), 5076-5085, 2008
3462008
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib
R Katayama, L Friboulet, S Koike, EL Lockerman, TM Khan, JF Gainor, ...
Clinical cancer research 20 (22), 5686-5696, 2014
3342014
Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function
Y Hao, K Sekine, A Kawabata, H Nakamura, T Ishioka, H Ohata, ...
Nature cell biology 6 (9), 849-860, 2004
3192004
Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine
R Katayama, CM Lovly, AT Shaw
Clinical Cancer Research 21 (10), 2227-2235, 2015
2802015
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
B Gong, K Kiyotani, S Sakata, S Nagano, S Kumehara, S Baba, B Besse, ...
Journal of Experimental Medicine 216 (4), 982-1000, 2019
2272019
Cabozantinib overcomes crizotinib resistance in ROS1 fusion–positive cancer
R Katayama, Y Kobayashi, L Friboulet, EL Lockerman, S Koike, AT Shaw, ...
Clinical cancer research 21 (1), 166-174, 2015
2192015
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition
R Katayama, A Aoyama, T Yamori, J Qi, T Oh-hara, Y Song, JA Engelman, ...
Cancer research 73 (10), 3087-3096, 2013
2172013
The system can't perform the operation now. Try again later.
Articles 1–20